EDNRA and pulmonary arterial hypertension: A study by Becker et al. reported that anti-AT1R and anti-ETAR antibodies were more frequently detectable in SSc-PAH or other CTDs vs. other forms of pulmonary hypertension and may serve as prognostic and predictive biomarkers in rheumatological patients [42].